Unravel begins with patients, using their RNA to define each disease using unbiased molecular data to power our systems biology approach. BioNAV, our proprietary probabilistic network model of human health, predicts molecules to restore a disease back to health, screening 40,000+ compunds in silico with 200x the hit rate of typical drug screens.

Our in vivo screening platform, SquishyWare, further downselects hits that work in a whole organism, letting us ask clinically-relevant questions from the start. We then use the off-target effects of existing drugs to validate new, hidden drug targets in real patients in the clinic, and in parallel develop new, highly effective therapies.

Unlike most other AI platforms, we have gone beyond preclinical studies and shown clinical translation of our platform through working directly with clinicians treating rare disorder patients. To-date, we have enabled doctors to achieve 100% clinical success in patients by predicting drugs that can be used to engage novel therapeutic targets. It has been so successful that we developed the rareSHIFT service program to provide patients and foundations access to our platform.